Maen Hussein

机构：Sarah Cannon, Florida Cancer Specialists & Research Institute · ORCID：0000-0001-6160-6776

发表论文 94 篇 · 总被引 5697 次 · h-index 23

代表论文

• Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial (2023 · Cancer Discovery · 被引 126)
• Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial (2024 · Journal of Thoracic Oncology · 被引 70)
• RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 38)
• A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study (2024 · Clinical Lung Cancer · 被引 15)
• Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report (2025 · Journal of Thoracic Oncology · 被引 13)
• Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study (2024 · BMC Cancer · 被引 13)